Cargando…

Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective

PURPOSE: The use process for chimeric antigen receptor T (CAR-T) cell drugs is complex and has been associated with a number of potentially severe complications, which requires management by a multidisciplinary team. Pharmacists are a key element in the team and have roles and responsibilities. Our...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzal-Alfaro, María Belen, Escudero-Vilaplana, Vicente, Revuelta-Herrero, Jose Luis, Collado-Borrell, Roberto, Herranz-Alonso, Ana, Sanjurjo-Saez, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992774/
https://www.ncbi.nlm.nih.gov/pubmed/33777790
http://dx.doi.org/10.3389/fonc.2021.636068
_version_ 1783669448854470656
author Marzal-Alfaro, María Belen
Escudero-Vilaplana, Vicente
Revuelta-Herrero, Jose Luis
Collado-Borrell, Roberto
Herranz-Alonso, Ana
Sanjurjo-Saez, Maria
author_facet Marzal-Alfaro, María Belen
Escudero-Vilaplana, Vicente
Revuelta-Herrero, Jose Luis
Collado-Borrell, Roberto
Herranz-Alonso, Ana
Sanjurjo-Saez, Maria
author_sort Marzal-Alfaro, María Belen
collection PubMed
description PURPOSE: The use process for chimeric antigen receptor T (CAR-T) cell drugs is complex and has been associated with a number of potentially severe complications, which requires management by a multidisciplinary team. Pharmacists are a key element in the team and have roles and responsibilities. Our objective was to develop a structured and practical guide that supports hospital pharmacist responsibilities and defines specific activities in a CAR-T cell therapy program, specifically in Europe. METHODS: A literature review was performed, and the recommendations related to pharmacy practice in CAR-T therapy programs were analyzed. A multidisciplinary team was assembled, and meetings were held to address the key tasks in the CAR-T cells’ management process and to create the guide, based on national and international recommendations and in expert’s opinions. RESULTS: The multidisciplinary team defined the following key tasks and issued recommendations to improve patient safety, treatment efficacy, and quality: patient selection and evaluation, CAR-T cell drug order to manufacturer, apheresis and material shipment, reception of CAR-T cell drug and storing, CAR-T cell drug prescription and pharmacy verification, CAR-T cell drug thawing and dispensing, CAR-T cell drug administration, patient education, pharmacovigilance and monitoring and outcomes’ record and evaluation. In each task the pharmacist’s role and how it can improve patient care are defined. A checklist was created to guarantee the compliance of standard operating procedures approved in the institution to manage CAR-T cell therapy and as a tool to collect required data for outcomes’ record and evaluation. CONCLUSION: This article provides a consensus set of safety recommendations regarding CAR-T therapy management in clinical practice, easily implementable by other institutions in the European setting. The guide identifies key steps where the involvement of hospital pharmacists would improve the safety and quality of the process and is a support guide to standardize hospital pharmacists’ responsibilities within the multidisciplinary team.
format Online
Article
Text
id pubmed-7992774
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79927742021-03-26 Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective Marzal-Alfaro, María Belen Escudero-Vilaplana, Vicente Revuelta-Herrero, Jose Luis Collado-Borrell, Roberto Herranz-Alonso, Ana Sanjurjo-Saez, Maria Front Oncol Oncology PURPOSE: The use process for chimeric antigen receptor T (CAR-T) cell drugs is complex and has been associated with a number of potentially severe complications, which requires management by a multidisciplinary team. Pharmacists are a key element in the team and have roles and responsibilities. Our objective was to develop a structured and practical guide that supports hospital pharmacist responsibilities and defines specific activities in a CAR-T cell therapy program, specifically in Europe. METHODS: A literature review was performed, and the recommendations related to pharmacy practice in CAR-T therapy programs were analyzed. A multidisciplinary team was assembled, and meetings were held to address the key tasks in the CAR-T cells’ management process and to create the guide, based on national and international recommendations and in expert’s opinions. RESULTS: The multidisciplinary team defined the following key tasks and issued recommendations to improve patient safety, treatment efficacy, and quality: patient selection and evaluation, CAR-T cell drug order to manufacturer, apheresis and material shipment, reception of CAR-T cell drug and storing, CAR-T cell drug prescription and pharmacy verification, CAR-T cell drug thawing and dispensing, CAR-T cell drug administration, patient education, pharmacovigilance and monitoring and outcomes’ record and evaluation. In each task the pharmacist’s role and how it can improve patient care are defined. A checklist was created to guarantee the compliance of standard operating procedures approved in the institution to manage CAR-T cell therapy and as a tool to collect required data for outcomes’ record and evaluation. CONCLUSION: This article provides a consensus set of safety recommendations regarding CAR-T therapy management in clinical practice, easily implementable by other institutions in the European setting. The guide identifies key steps where the involvement of hospital pharmacists would improve the safety and quality of the process and is a support guide to standardize hospital pharmacists’ responsibilities within the multidisciplinary team. Frontiers Media S.A. 2021-03-11 /pmc/articles/PMC7992774/ /pubmed/33777790 http://dx.doi.org/10.3389/fonc.2021.636068 Text en Copyright © 2021 Marzal-Alfaro, Escudero-Vilaplana, Revuelta-Herrero, Collado-Borrell, Herranz-Alonso and Sanjurjo-Saez http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Marzal-Alfaro, María Belen
Escudero-Vilaplana, Vicente
Revuelta-Herrero, Jose Luis
Collado-Borrell, Roberto
Herranz-Alonso, Ana
Sanjurjo-Saez, Maria
Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
title Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
title_full Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
title_fullStr Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
title_full_unstemmed Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
title_short Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
title_sort chimeric antigen receptor t cell therapy management and safety: a practical tool from a multidisciplinary team perspective
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992774/
https://www.ncbi.nlm.nih.gov/pubmed/33777790
http://dx.doi.org/10.3389/fonc.2021.636068
work_keys_str_mv AT marzalalfaromariabelen chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective
AT escuderovilaplanavicente chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective
AT revueltaherrerojoseluis chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective
AT colladoborrellroberto chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective
AT herranzalonsoana chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective
AT sanjurjosaezmaria chimericantigenreceptortcelltherapymanagementandsafetyapracticaltoolfromamultidisciplinaryteamperspective